SCHEMBL7180844

SCHEMBL7180844

CCCCP(=O)(C(=O)c1c(C)cc(C(C)(C)C)cc1C)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.39
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
GAA P10253 2/20 0.37
ALDH1A1 P00352 1/20 0.37
PKM P14618 1/20 0.37
CETP P11597 3/20 0.35
HDAC3 O15379 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC2 Q92769 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
LMNA P02545 2/20 0.35
NPSR1 Q6W5P4 1/20 0.35
POLB P06746 2/20 0.35
NR5A2 O00482 1/20 0.34
NR5A1 Q13285 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7177648 0.96 CETP (0.40) TSHRMEN1KMT2AGAAALDH1A1
SCHEMBL7189024 0.95 CETP (0.42) TSHRMEN1KMT2AGAAALDH1A1
SCHEMBL7181959 0.95 CETP (0.42) TSHRMEN1KMT2AGAAALDH1A1
SCHEMBL7188525 0.95 CETP (0.42) TSHRMEN1KMT2AGAAALDH1A1
SCHEMBL7179947 0.95 CETP (0.42) TSHRMEN1KMT2AGAAALDH1A1
SCHEMBL7179807 0.92 LMNA (0.39) TSHRMEN1KMT2AGAAALDH1A1
SCHEMBL7182680 0.88 TSHR (0.41) TSHRMEN1KMT2ACETPLMNA
SCHEMBL7183766 0.86 MEN1 (0.44) TSHRMEN1KMT2AGAAALDH1A1
SCHEMBL7180888 0.86 TSHR (0.42) TSHRMEN1KMT2ACETPLMNA
SCHEMBL14570831 0.85 TSHR (0.41) TSHRMEN1KMT2ACETPLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 TSHR 984/4885MEN1 2312/4885KMT2A 1586/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 TSHR 1273/4885MEN1 2263/4885KMT2A 956/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.